top of page

Vijay Padul, PhD

Sr. Scientist – Omics

Vijay Padul is a Senior Scientist at Rhenix, who leads bioinformatics, genomics, and Next Generation Sequencing research-related activities, in the organization. He is currently working on the neoantigen cancer vaccine pipeline projects, here.

Vijay holds a Ph.D. in Life Sciences from TMC-ACTREC, Homi Bhabha National Institute, Navi Mumbai. His Ph.D. study focused on Cancer Genomics. Previously, Vijay has worked as Assistant Professor at graduate and post-graduate degree colleges as well.

At Rhenix, he has gained experience in scientific, operational, and administrative matters.

Stories

Summary "A phase Ib-IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma- CUSP9v3-2021"

Glioblastoma is the most common and aggressive primary malignant brain tumor in adults. Despite therapeutic interventions, glioblastoma prognosis remains very poor as most patients die…

Glioblastoma Multiforme - VP.jpg

Summary "Uncovering the link between chromatin activity, gene expression in myeloid cells, and Alzheimer’s disease risk."

Alzheimer’s disease (AD) is a progressive neurological disorder commonly affecting people older than 65 years of age. The neurodegenerative progression of the disorder causes...

Alzheimer's disease.jpg

Summary "An effective integrated grading system for meningioma tumor grading that incorporates molecular features."

Meningioma is the most common primary intracranial tumor in the United States. There are approximately 35,000 new cases diagnosed every year. meningioma has an estimated population prevalence of approximately...

Meningioma

Summary "Multi-omic analysis of low-grade glioma histological subtypes uncovers the significance of tumor purity."

Astrocytoma and Oligodendroglioma are the histological subtypes of glioma brain tumors. Histological classification of gliomas has been the clinical practice before the inclusion of molecular markers by the...

Astrocytoma.jpg

Videos

A phase Ib-IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma- CUSP9v3-2021 | CellTalk

Glioblastoma is the most common and most aggressive primary malignant brain tumor in adults. Despite therapeutic interventions, the glioblastoma prognosis remains very poor as most patients die within 12 months after diagnosis...

Uncovering the link between chromatin activity, gene expression in myeloid cells, and Alzheimer’s disease risk | CellTalk

Alzheimer’s disease (AD) is a progressive neurological disorder commonly affecting people older than 65 years of age. The neurodegenerative progression of the disorder causes the death of the brain cells which results in brain atrophy...

An effective integrated grading system for meningioma tumor grading that incorporates molecular features | CellTalk

Meningioma is the most common primary intracranial tumor in the United States. There are approximately 35,000 new cases diagnosed every year. meningioma has an estimated population prevalence of approximately 1 in every...

Multi-omic analysis of low-grade glioma histological subtypes uncovers the significance of tumor purity | CellTalk

Astrocytoma and Oligodendroglioma are the histological subtypes of glioma brain tumors. Histological classification of gliomas has been the clinical practice before the inclusion of molecular markers by the World Health Organization (WHO) Classification...

Connecting Dots

Get the latest updates

Join Celltalk!

Subscribe us today & receive latest updates on your mail !

bottom of page